Tenofovir alafenamide , a new once-daily oral prodrug of tenofovir , showed more potent anti-HIV-@ activity and higher intracellular tenofovir levels compared with tenofovir disoproxil fumarate , while maintaining lower plasma tenofovir exposure at @ mg with good tolerability over @ days of monotherapy .